Sagent Recalls Four Lots of Levetiracetam
The antiseizure medication affected by the recall could have sterility issues.
Sagent Pharmaceuticals is recalling four lots of Levetiracetam Injection, which is used for the treatment of certain types of seizures. It is packaged in a 5 mL single-does vial and was distributed from March 2021 until November 2021.
The recall is because of a lack of container closure integrity, which could lead to sterility issues. To date, Sagent has not received reports of any product complaints or adverse events associated with this issue.
The NDC number of the affected product is 25021-780-05. The lot numbers included in the recall include:
- B0G85VB, with an expiration date of June 2022
- B0K88VA, with an expiration date of September 2022
- B0K89VA, with an expiration date of September 2022
- B1G194A, with an expiration date of June 2023
Levetiracetam label
FDA Clears Phase 2 Trial of Cannabis in PTSD
November 20th 2024After a three-year negotiation, the FDA has dropped its objection to allowing patients to self-titrate dosing of smoked cannabis. But regulators want to see additional information about the device that will be used for inhalation.
Read More
